FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128183896> ?p ?o ?g. }

• W2128183896 endingPage "2348" @default.
• W2128183896 startingPage "2339" @default.
• W2128183896 abstract "Our study demonstrates the glioma tumor antigen podoplanin to be present at very high levels (>90%) in both glioblastoma (D2159MG, D08-0308MG and D08-0493MG) and medulloblastoma (D283MED, D425MED and DAOY) xenografts and cell line. We constructed a novel recombinant single-chain antibody variable region fragment (scFv), NZ-1, specific for podoplanin from the NZ-1 hybridoma. NZ-1-scFv was then fused to Pseudomonas exotoxin A, carrying a C-terminal KDEL peptide (NZ-1-PE38KDEL). The immunotoxin (IT) was further stabilized by a disulfide (ds) bond between the heavy-chain and light-chain variable regions as the construct NZ-1-(scdsFv)-PE38KDEL. NZ-1-(scdsFv)-PE38KDEL exhibited significant reactivity to glioblastoma and medulloblastoma cells. The affinity of NZ-1-(scdsFv), NZ-1-(scdsFv)-PE38KDEL and NZ-1 antibody for podoplanin peptide was 2.1 × 10(-8) M, 8.0 × 10(-8) M and 3.9 × 10(-10) M, respectively. In a protein stability assay, NZ-1-(scdsFv)-PE38KDEL retained 33-98% of its activity, whereas that of NZ-1-PE38KDEL declined to 13% of its initial levels after incubation at 37°C for 3 days. In vitro cytotoxicity of the NZ-1-(scdsFv)-PE38KDEL was measured in cells isolated from glioblastoma xenografts, D2159MG, D08-0308MG and D08-0493MG, and in the medulloblastoma D283MED, D425MED and DOAY xenografts and cell line. The NZ-1-(scdsFv)-PE38KDEL IT was highly cytotoxic, with an 50% inhibitory concentration in the range of 1.6-29 ng/ml. Significantly, NZ-1-(scdsFv)-PE38KDEL demonstrated tumor growth delay, averaging 24 days (p < 0.001) and 21 days (p < 0.001) in D2159MG and D283MED in vivo tumor models, respectively. Crucially, in the D425MED intracranial tumor model, NZ-1-(scdsFv)-PE38KDEL caused a 41% increase in survival (p ≤ 0.001). In preclinical studies, NZ-1-(scdsFv)-PE38KDEL exhibited significant potential as a targeting agent for malignant brain tumors." @default.
• W2128183896 created "2016-06-24" @default.
• W2128183896 creator A5004814459 @default.
• W2128183896 creator A5025528414 @default.
• W2128183896 creator A5027965720 @default.
• W2128183896 creator A5037367015 @default.
• W2128183896 creator A5052288586 @default.
• W2128183896 creator A5056573254 @default.
• W2128183896 creator A5060119598 @default.
• W2128183896 creator A5071828386 @default.
• W2128183896 creator A5090041608 @default.
• W2128183896 date "2012-11-23" @default.
• W2128183896 modified "2023-10-16" @default.
• W2128183896 title "Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors" @default.
• W2128183896 cites W1558897349 @default.
• W2128183896 cites W1886985639 @default.
• W2128183896 cites W1929145004 @default.
• W2128183896 cites W1982754402 @default.
• W2128183896 cites W1987981887 @default.
• W2128183896 cites W2003299637 @default.
• W2128183896 cites W2016821076 @default.
• W2128183896 cites W2018848776 @default.
• W2128183896 cites W2019088224 @default.
• W2128183896 cites W2067899969 @default.
• W2128183896 cites W2075925060 @default.
• W2128183896 cites W2080576795 @default.
• W2128183896 cites W2084558110 @default.
• W2128183896 cites W2091977407 @default.
• W2128183896 cites W2092769047 @default.
• W2128183896 cites W2093783077 @default.
• W2128183896 cites W2096287682 @default.
• W2128183896 cites W2096523189 @default.
• W2128183896 cites W2099366913 @default.
• W2128183896 cites W2114052327 @default.
• W2128183896 cites W2117557895 @default.
• W2128183896 cites W2118925058 @default.
• W2128183896 cites W2120391794 @default.
• W2128183896 cites W2123857764 @default.
• W2128183896 cites W2128585791 @default.
• W2128183896 cites W2139816948 @default.
• W2128183896 cites W2143594378 @default.
• W2128183896 cites W2148583422 @default.
• W2128183896 cites W2151335185 @default.
• W2128183896 cites W2151853926 @default.
• W2128183896 doi "https://doi.org/10.1002/ijc.27919" @default.
• W2128183896 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3809846" @default.
• W2128183896 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23115013" @default.
• W2128183896 hasPublicationYear "2012" @default.
• W2128183896 type Work @default.
• W2128183896 sameAs 2128183896 @default.
• W2128183896 citedByCount "66" @default.
• W2128183896 countsByYear W21281838962013 @default.
• W2128183896 countsByYear W21281838962014 @default.
• W2128183896 countsByYear W21281838962015 @default.
• W2128183896 countsByYear W21281838962016 @default.
• W2128183896 countsByYear W21281838962017 @default.
• W2128183896 countsByYear W21281838962018 @default.
• W2128183896 countsByYear W21281838962019 @default.
• W2128183896 countsByYear W21281838962020 @default.
• W2128183896 countsByYear W21281838962021 @default.
• W2128183896 countsByYear W21281838962022 @default.
• W2128183896 countsByYear W21281838962023 @default.
• W2128183896 crossrefType "journal-article" @default.
• W2128183896 hasAuthorship W2128183896A5004814459 @default.
• W2128183896 hasAuthorship W2128183896A5025528414 @default.
• W2128183896 hasAuthorship W2128183896A5027965720 @default.
• W2128183896 hasAuthorship W2128183896A5037367015 @default.
• W2128183896 hasAuthorship W2128183896A5052288586 @default.
• W2128183896 hasAuthorship W2128183896A5056573254 @default.
• W2128183896 hasAuthorship W2128183896A5060119598 @default.
• W2128183896 hasAuthorship W2128183896A5071828386 @default.
• W2128183896 hasAuthorship W2128183896A5090041608 @default.
• W2128183896 hasBestOaLocation W21281838961 @default.
• W2128183896 hasConcept C109316439 @default.
• W2128183896 hasConcept C115085202 @default.
• W2128183896 hasConcept C153911025 @default.
• W2128183896 hasConcept C154317977 @default.
• W2128183896 hasConcept C159654299 @default.
• W2128183896 hasConcept C182179738 @default.
• W2128183896 hasConcept C202751555 @default.
• W2128183896 hasConcept C203014093 @default.
• W2128183896 hasConcept C2778227246 @default.
• W2128183896 hasConcept C502942594 @default.
• W2128183896 hasConcept C55493867 @default.
• W2128183896 hasConcept C86803240 @default.
• W2128183896 hasConceptScore W2128183896C109316439 @default.
• W2128183896 hasConceptScore W2128183896C115085202 @default.
• W2128183896 hasConceptScore W2128183896C153911025 @default.
• W2128183896 hasConceptScore W2128183896C154317977 @default.
• W2128183896 hasConceptScore W2128183896C159654299 @default.
• W2128183896 hasConceptScore W2128183896C182179738 @default.
• W2128183896 hasConceptScore W2128183896C202751555 @default.
• W2128183896 hasConceptScore W2128183896C203014093 @default.
• W2128183896 hasConceptScore W2128183896C2778227246 @default.
• W2128183896 hasConceptScore W2128183896C502942594 @default.
• W2128183896 hasConceptScore W2128183896C55493867 @default.
• W2128183896 hasConceptScore W2128183896C86803240 @default.
• W2128183896 hasIssue "10" @default.

• next